InVitae's 211-Gene Test in Early Access as It Aims for Sub-$1,000 Test for 1,000 Disorders | GenomeWeb

Genetic testing company InVitae said last week that its 211-gene sequencing-based assay that screens for just over 260 genetic conditions is now being offered to early-access customers.

In a presentation at Cambridge Healthtech Institute's Clinical Genome Conference in San Francisco last week, CEO Randy Scott said that the company is working with 20 to 30 early-access physicians.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.